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Abstract 
Background  Little information exists about the role of anemia in patients with acute coronary syndromes (ACS) admitted to Intensive 
Cardiac Care Units (ICCU). The aim of this study was to assess the prevalence of anemia and its impact on management and outcomes in 
this clinical setting. Methods  All consecutive patients admitted to eight different ICCUs with diagnosis of non-ST segment elevation ACS 
(NSTEACS) were prospectively included. Anemia was defined as hemoglobin < 130 g/L in men and < 120 g/L in women. The association 
between anemia and mortality or readmission at six months was assessed by the Cox regression method. Results  A total of 629 patients 
were included. Mean age was 66.6 years. A total of 197 patients (31.3%) had anemia. Coronary angiography was performed in most patients 
(96.2%). Patients with anemia were significantly older, with a higher prevalence of comorbidities, poorer left ventricle ejection fraction and 
higher GRACE score values. Patients with anemia underwent less often coronary angiography, but underwent more often intraaortic coun-
terpulsation, non-invasive mechanical ventilation and renal replacement therapies. Both ICCU and hospital stay were significantly longer in 
patients with anemia. Both the incidence of mortality (HR = 3.36, 95% CI: 1.43–7.85, P = 0.001) and the incidence of mortality/readmission 
were significantly higher in patients with anemia (HR = 2.80, 95% CI: 2.03–3.86, P = 0.001). After adjusting for confounders, the association 
between anemia and mortality/readmission remained significant (P = 0.031). Conclusions  Almost one of three NSTEACS patients admit-
ted to ICCU had anemia. Most patients underwent coronary angiography. Anemia was independently associated to poorer outcomes at 6 
months. 
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1  Introduction 
Anemia is a common clinical condition in patients with 
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acute coronary syndromes (ACS), especially in elderly pa-
tients with comorbidities.[1] The progressive ageing of 
population is leading to an increase in the number of pa-
tients with ACS and anemia.[2] Importantly, patients with 
anemia are usually excluded from clinical trials, and infor-
mation regarding their optimal management is scarce.[3] 
Patients with anemia are commonly managed conserva-
tively in routine clinical practice.[4,5] In a not negligible 
proportion of cases, these patients are denied intensive 
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therapies because of perception of short life expectancy and 
fear of complications. Little information exists about anemia 
in ACS patients admitted to intensive care units.[6,7] The aim 
of this study was to assess the prevalence of anemia and its 
impact on management and outcomes in consecutive pa-
tients with non ST segment elevation ACS (NSTEACS) 
admitted to Intensive Cardiac care Units (ICCU). 
2  Methods 
2.1  Design and study population  
This is a multicenter registry carried out in eight hospitals 
of Catalonia during a period of 6 months (between October 
1, 2017 to March 31, 2018). This study was endorsed and 
coordinated by the Working Group on Acute Cardiac Care 
of the Catalan Society of Cardiology. 
All consecutive patients admitted to the ICCUs of the 
participating centers with a diagnosis of NSTEACS were 
prospectively included. NSTEACS was defined as the 
presence of chest pain compatible with acute coronary syn-
drome with at least one of the following: (1) electrocardio-
graphic abnormalities suggesting myocardial ischemia and 
(2) elevation of troponin. The only exclusion criteria was 
the impossibility of obtaining informed consent for partici-
pation in the registry.  
2.2  Data collection  
Data were prospectively collected during admission by 
local researchers, using specific standardized case report 
forms. Demographic data, baseline clinical characteristics, 
analytical, electrocardiographic and echocardiographic data 
were recorded, as well as the performance of coronary an-
giography. Information about in-hospital clinical course 
(treatments administered, requirement of invasive proce-
dures, complications and in-hospital mortality) was also 
collected. The CRUSADE[8] and GRACE[9] risk scores were 
calculated for each patient. The hemodynamic parameters 
(heart rate, systolic blood pressure) and Killip class were 
recorded upon admission to the ICCU. Creatinin clearance 
was calculated by the Cockcroft-Gault formula.[10] Body 
surface area was calculated using the Mosteller formula.[11] 
Anemia at admission was defined by the World Health 
Organisation criteria (hemoglobin < 130 g/L in men and < 
120 g/L in women).[12] 
Patients’ risk profile was defined by the criteria of the 
European Society of Cardiology.[13] Patients with very high 
risk were considered those who presented at least one of the 
following conditions: refractory angina, hemodynamic in-
stability, cardiogenic shock, acute heart failure, ventricular 
arrhythmias or cardiorespiratory arrest. Likewise, high-risk 
patients were considered those with elevated serum troponin, 
diabetes mellitus or GRACE scale values > 140, without 
very high risk criteria.  
Management of patients was done according to current 
recommendations. Antithrombotic treatment and coronary 
angiography were left to the discretion of the medical team. 
If coronary angiography was performed, vascular access, 
antithrombotic drugs and the choice of stents and other 
devices were lead to operator’s decision.  
Clinical follow-up was carried out at six months by 
medical visit, review of medical records or telephone 
contact with the patient, family or referring physician. The 
main outcome measured of the study was mortality or re-
admission at six months of follow-up. The assignment of 
the cause of death was based on clinical judgment of the 
physician taking care of the patient at the time of death. 
Death was deemed cardiac when it was be due to myocar-
dial infarction, heart failure or sudden death. The incidence 
of reinfarction and new coronary revascularizations were 
also recorded.  
2.3  Statistical analysis  
The analysis of normal distribution of variables was per-
formed using the Shapiro-Wilk test. Quantitative variables 
are expressed as mean ± SD. Non-normally distributed 
variables are expressed as median and interquartile range. 
Categorical variables are expressed as number and percentage. 
Baseline characteristics, clinical management and in-hos-
pital clinical course were compared across if anemia was 
present. The association between categorical variables was 
analyzed with the Chi-square test, with the correction of 
continuity when indicated. The analysis of quantitative 
variables according to anemia status was performed by Stu-
dent’s t test. The association between anemia and mortality 
or readmission at 6 months was assessed by the Cox regres-
sion method. Variables included in the multivariate analy-
sis[14] were those with an association (P < 0.2) both with 
exposition (anemia) and effect (mortality or readmission at 
6 months, see table), and not considered to be an intermedi-
ate variable between them.  
Survival analysis was performed using Kaplan Meier 
curves. Statistical significance of differences was assessed 
by log rank test. The PASW Statistics 18 (Chicago, IL, USA) 
was used for all analysis. 
3  Results 
A total of 629 patients were included across the study pe-
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riod, of whom 483 (76.7%) were male. Mean age was 66.6 
years. 
Globally, patients from this series had a high risk profile, 
with a significant proportion of comorbidities such as dia-
betes mellitus (238/629, 37.8%), peripheral artery disease 
(106/629, 16.9%) or previous stroke (56/629, 8.9%). Most 
patients had elevated serum troponin levels (574/629, 
91.3%), and almost one of each five patients had signs of 
heart failure at admission (119/629, 18.9%). Coronary an-
giography during the admission was performed in the vast 
majority of patients (605/629, 96.2%). A total of 197 pa-
tients (31.3%) had anemia at admission. 
3.1  Clinical characteristics according to anemia status 
Patients with anemia were significantly older, with a 
higher prevalence of cardiovascular risk factors and comor-
bidities such as peripheral artery disease, previous stroke or 
previous malignancy. They also had a higher prevalence of 
previous myocardial infarction and higher degree of comor-
bidity as measured by the Charlson index (Table 1). Patients  
Table 1.  Clinical characteristics according to anemia status. 
 Anemia (n = 197) No anemia (n = 432) P-value 
Age, yrs 71.6 ± 11 64.3 ± 12 0.001 
Male sex 154 (78.2%) 329 (76.2%) 0.579 
BMI, kg/m2 27.3 (7%) 27.9 (5%) 0.201 
BSA, m2 1.85 (0.2%) 1.91 (0.2%) 0.001 
Active smoking 31 (15.8%) 151 (35.3%) 0.001 
Diabetes mellitus 110 (55.8%) 128 (29.6%) 0.001 
Hypertension 173 (88.3%) 289 (66.9%) 0.001 
Dyslipidemia 161 (83%) 373 (63.3%) 0.001 
Previous myocardial infarction 74 (37.8%) 89 (20.7%) 0.001 
Previous percutaneous coronary intervention 63 (32.1%) 78 (18.1%) 0.001 
Previous treatment with ASA 122 (61.9%) 124 (28.7%) 0.001 
Previous treatment with P2Y12 inhibitors 49 (24.9%) 57 (13.2%) 0.001 
Previous treatment with OAC 22 (11.1%) 45 (10.4%) 0.745 
Previous heart failure 22 (11.2%) 33 (7.7%) 0.143 
Previous atrial fibrillation 23 (11.7%) 43 (10%) 0.501 
Previous stroke 27 (13.7%) 29 (6.7%) 0.009 
Peripheral artery disease 52 (26.4%) 54 (12.5%) 0.001 
Previous malignancy 35 (17.9%) 45 (10.4%) 0.010 
Previous bleeding 16 (8.2%) 13 (3%) 0.004 
Charlson comorbidity index 3.2 ± 2% 2.2 ± 2 0.001 
Clinical characteristics 
Creatinine clearance, mL/min 60 (35%) 99 (41%) 0.001 
Haemoglobin at admission, g/dL 10.9 (1.4%) 14.5 (1.2%) 0.001 
Glucose at admission, mg/dL 165 (84%) 146 (77%) 0.008 
LDL cholesterol, mg/dL 77 (29%) 106 (72%) 0.001 
Killip class at admission > I 65 (33%) 54 (12.5%) 0.001 
Systolic blood pressure, mmHg 138 (25%) 137 (26%) 0.712 
Heart rate, beats/min 80 (20%) 78 (17%) 0.065 
Positive troponin 180 (91.4%) 394 (91.2%) 0.945 
GRACE score 156 ± 34 133 ± 34 0.001 
CRUSADE score  43 ± 17  22 ± 14 0.001 
PRECISE-DAPT score  35 ± 15  17 ± 12 0.001 
High-risk criteria 102 (51.8%) 290 (67.6%) 0.001 
Very high risk criteria 93 (47.2%) 132 (30.8%) 0.001 
Data are presented as mean ± SD or n (%). ASA: acetilsalicyilic acid; BMI: body mass index; BSA: body surface area; LDL: low density lipoprotein; OAC: 
oral anticoagulant drugs. 
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with anemia had also poorer renal function and higher glu-
cose levels at admission and lower levels of LDL choles-
terol. These patients had higher risk criteria than the rest of 
patients, with a higher incidence of heart failure at admis-
sion, poorer left ventricle ejection fraction and higher 
GRACE, CRUSADE and PRECISE-DAPT scores values. 
3.2  In hospital clinical management and outcomes  
according to anemia status 
Patients with anemia underwent less often coronary an-
giography during the admission, with a higher proportion of 
multivessel disease and left main coronary stenosis, but 
without significant differences regarding coronary revascu-
larization (Table 2).  
Significant differences were also observed regarding 
in-hospital medical treatment, with a higher proportion of 
treatment with clopidogrel, amiodarone, diuretics and iv-
abradine and a lower proportion of treatment with ticagrelor 
and ACE inhibitors in patients with anemia. In addition, 
these patients underwent more often invasive in-hospital 
Table 2.  In-hospital management according to anemia status. 
 Anemia (n = 197) No anemia (n = 432) P-value 
In-hospital medical treatment 
ASA 195 (99%) 431 (99%) 0.183 
Clopidogrel 158 (80.6%) 257 (60%) 0.001 
Ticagrelor 42 (21.3%) 187 (43.4%) 0.001 
Prasugrel 6 (3.1%) 24 (5.6%) 0.226 
Enoxaparin 101 (51.8%) 246 (57.6%) 0.175 
Fondaparinux 44 (22.7%) 117 (27.3%) 0.225 
Unfractionated heparin 54 (27.7%) 108 (25.2%) 0.506 
Abciximab 2 (1%) 2 (0.5%) 0.373 
Inotropes 19 (9.6%) 28 (6.5%) 0.169 
Amiodarone 19 (9.6%) 21 (4.9%) 0.023 
Diuretics 106 (54.1%) 110 (25.6%) 0.001 
Betablockers 154 (78.2%) 344 (80.8%) 0.455 
Ivabradin 16 (8.1%) 15 (3.5%) 0.013 
Ranolazine 5 (2.5%) 4 (0.9%) 0.149 
ACEI 114 (58.2%) 301 (70.3%) 0.003 
Eplerenone 18 (9.1%) 26 (6.1%) 0.167 
Statins 193 (98%) 420 (97.4%) 0.786 
Ezetimibe 10 (5.1%) 23 (5.4%) 0.882 
Insulin 113 (57.4%) 136 (31.6%) 0.001 
Oral antidiabetic drugs 8 (4.1%) 17  (4%) 0.948 
Proton pump inhibitors 196 (99.5%) 416 (97.2%) 0.117 
In-hospital procedures 
Angiography 181 (91.9%) 424 (98.1%) 0.001 
Time to angiography, h 21.8 (4–61) 19.6 (3–44) 0.123 
Multivessel disease 109 (60.2%) 191 (45%) 0.009 














Temporary pacemaker 7 (3.6%) 8 (1.9%) 0.193 
Intraaortic counterpulsation 12 (6.1%) 9 (2.1%) 0.015 
Invasive mechanical ventilation 24 (12.2%) 44 (10.2%) 0.453 
Non-invasive mechanical ventilation 26 (13.2%) 20 (4.6%) 0.001 
Therapeutic hypothermia 0 4 (0.9%) 0.417 
Renal replacement therapies 13 (6.6%) 3 (0.7%) 0.001 
High flow nasal cannula 12 (6.1%) 9 (2.1%) 0.015 
Data are presented as n (%) or median (interquartile range). ASA: acetil salycilic acid; ACEI: angiotensin converter enzyme inhibitors. 
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(n = 197) 
No anemia 
(n = 432) 
P-value
Refractory ischemia 20 (10.2%) 16 (3.7%) 0.002 
Reinfarction 6 (3.1%) 5 (1.2%) 0.107 
Atrioventricular block 9 (4.6%) 5 (1.2%) 0.015 
Ventricular fibrillation 3 (1.5%) 6 (1.4%) 0.895 
Atrial fibrillation 28 (14.4%) 31(7.2%) 0.005 
Stroke 0 3 (0.7%) 0.584 
CRUSADE major bleeding 17 (8.6%) 44 (10.2%) 0.541 
Need for transfusion 14 (77.8%) 11 (44%) 0.027 
In-hospital mortality 3 (1.5%) 9 (2.1%) 0.634 
ICCU stay 3 (2–5) 3 (2–4) 0.013 
Hospital stay 9 (5–15) 6 (4–10) 0.001 
Data are presented as n (%) or median (interquartile range). ICCU: Inten-
sive cardiac Care Unit. 
 
procedures such as intraaortic counterpulsation, non-in-
vasive mechanical ventilation and renal replacement thera-
pies as compared to patients without anemia. 
Patients with anemia had a higher incidence of in-hos-
pital complications such as refractory ischemia, atrioven-
tricular block or atrial fibrillation, without differences in the 
rate of major bleeding or in-hospital mortality. Both ICU 
and in-hospital stay were significantly longer in patients 
with anemia (Table 3). 
3.3  Post-discharge management and clinical outcomes 
according to anemia status 
Patients with anemia were more commonly treated with 
clopidogrel, diuretics, ivabradine, ranolazine and proton 
pump inhibitors at hospital discharge (Table 4). In contrast, 
the rate of prescription of ticagrelor and prasugrel was sig-
nificantly lower in these patients. 
From 617 patients surviving at hospital discharge, data 
on clinical follow up was available in 586 cases (95%). Of 
them, 33 patients (5.6%) presented new ACS and 17 (2.9%) 
clinically significant bleeding at 6 months. 
Globally, a total of 23 patients died at 6 months and 140 
patients dead or were readmitted at 6 months. Both the in-
cidence of mortality (HR = 3.36, 95% CI: 1.43–7.85, P = 
0.001) and the incidence of mortality or readmission were 
significantly higher in patients with anemia (HR = 2.80, 
95% CI: 2.03–3.86, P = 0.001). After adjusting for potential 
confounders, the association between anemia and mortality 
or readmission at 6 months was still significant (HR = 2.22, 
95% CI: 1.32–3.71, P = 0.031, Table 5). Figure 1 shows the 
cumulative incidence of mortality and mortality or readmis-
sion at 6 months according to anemia status. 
4  Discussion 
The main findings from this study are: (1) a significant 
proportion (31.3%) of these patients with NSTEACS had 
anemia at admission to ICCU; (2) patients with anemia had 
a significantly higher prevalence of comorbidities and higher 
risk criteria at admission; (3) despite the proportion was 
lower in patients with anemia, the vast majority of patients 
underwent coronary angiography during the admission (96.2%), 
and (4) patients with anemia had a higher incidence of mor-
tality or readmission at 6 months, and this association was 
independent from potential confounders. 
Anemia is a common comorbidity in ACS, and is 
strongly associated with poorer clinical outcomes in these 
patients[15–20] and also in other clinical settings.[21,22] Preva-
lence of anemia in patients with ACS ranges between 20% 
30% in most series, and is especially higher in elderly pa-
tients with comorbidities.[23–25] In contrast, other studies 
including highly selected ACS patients from clinical tri-
als[26,27] or assessing only patients treated with potent anti-
platelet drugs[28] reported a significantly lower prevalence of 
anemia, around 10%. A not negligible proportion of patients 
with ACS and anemia are denied ICU admission in routine 
clinical practice because of a high degree of comorbidities 
and perception of a low life expectancy. Information about  




(n = 194) 
No anemia 
(n = 423) 
P-value
ASA 181 (93.3%) 394 (93.1%) 0.944 
Clopidogrel 114 (58.8%) 149 (35.2%) 0.001 
Ticagrelor 28 (14.4%) 151 (35.7%) 0.001 
Prasugrel 3 (1.5%) 24 (5.7%) 0.020 
Direct anticoagulants 8 (4.1%) 13 (3.1%) 0.497 
Vitamin K antagonists 18 (9.3%) 51 (12%) 0.314 
Amiodarone 10 (5.2%) 20 (4.7%) 0.819 
Diuretics 93 (47.9%) 101 (23.9%) 0.001 
Betablockers 146 (75.3%) 317 (75.1%) 0.970 
Ivabradin 22 (11.3%) 12 (2.8%) 0.001 
Ranolazine 9 (4.6%) 6 (1.4%) 0.034 
ACEI 98 (50.5%) 245 (57.9%) 0.086 
Eplerenone 21 (10.8%) 27 (6.4%) 0.056 
Statins 186 (95.9%) 391 (92.4%) 0.107 
Ezetimibe 17 (8.8%) 36 (8.6%) 0.937 
Insulin 61 (31.4%) 54 (12.8%) 0.001 
Oral antidiabetic drugs 68 (35.2%) 99 (23.6%) 0.003 
Proton pump inhibitors 173 (89.2%) 346 (81.8%) 0.020 
Data are presented as n (%). ASA: acetil salycilic acid; ACEI: angiotensin 
converter enzyme inhibitors. 
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Table 5.  Predictors of mortality or readmission at 6 months.  
Univariate analysis Multivariate analysis 
Variable  
Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value 
Anemia 2.80 (2.03–3.86) 0.001 2.22 (1.32–3.71) 0.031 
Age 1.03 (1.02–1.05) 0.001 1.02 (1.00–1.04) 0.062 
BSA 0.46 (0.21–1.02) 0.057   
Active smoking 0.88 (0.72–1.08) 0.229   
Diabetes 1.91 (1.39–2.64) 0.001   
Hypertension 1.94 (1.26–2.98) 0.002   
Dyslipidemia 1.56 (1.06–2.30) 0.025   
Peripheral artery disease 2.36 (1.66–3.37) 0.001 1.88 (1.27–2.79) 0.002 
Previous stroke 2.76 (1.89–4.02) 0.001 2.13 (1.41–3.22) 0.001 
Previous myocardial infarction 2.08 (1.49–2.89) 0.001   
Previous PCI 1.34 (0.93–1.92) 0.119   
Previous malignancy 1.66 (1.10–2.51) 0.016   
Previous bleeding 1.79 (0.97–3.30) 0.064   
Charlson comorbidity Index 1.22 (1.12–1.32) 0.001   
Killip class on admission >= II 2.69 (1.91–3.77) 0.001   
Heart rate 1.02 (1.01–1.02) 0.001   
Creatinin clearance 0.99 (0.98–0.99) 0.001   
Glucose at admission 1.00 (1.00–1.01) 0.001   
LDL cholesterol 0.99 (0.99–1.00) 0.041   
Left ventricle ejection fraction 0.97 (0.96–0.98) 0.001 0.99 (0.97–1.00) 0.082 
Multivessel disease 1.39 (0.99–1.96) 0.058 1.24 (1.02–1.50) 0.028 
Left main disease 2.01 (1.35–2.97) 0.001   
BSA: body surface area; PCI: percutaneous coronary intervention. 
 
Figure 1.  Cumulative incidence of mortality (A) and mortality or readmission at 6 months (B) according to anemia status. 
the real prevalence of anemia in high-risk ACS patients 
admitted to critical care units is scarce. In an interesting 
contribution, Uscinska, et al.[6] assessed a series of 392 pa-
tients admitted to an Intensive Cardiac Care Unit between 
2008–2011 (mean age, 70 ± 13.8 year). Of them, 168 
(42.9%) had diagnosis of ACS. The authors described a 
high prevalence of anemia according to WHO criteria in the 
whole cohort (64%), which was significantly lower in pa-
tients with ACS. Biomarkers of iron status but not anemia 
predicted in-hospital mortality. In another subanalysis of 
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that series,[7] haemoglobin levels—along with age, parame-
ters of iron status, and LVEF—were strong predictors of 
long-term mortality. Another small series[29] also described 
a high prevalence of anemia in ACS patients admitted to an 
ICCU. To our knowledge, no other study focused on ACS 
patients admitted to ICCU. Data from our study revealed 
that, despite being a relatively young population, almost one 
of each three of these high risk ACS patients admitted to 
ICCU had anemia at admission. This proportion is signifi-
cantly lower than those observed in the series by Uscinska, 
et al.[6] Ours was a significantly younger homogeneous po-
pulation in which we only assessed patients with NSTEACS 
diagnosis. On the other hand, different criteria for ICCU 
admission might also have contributed to the lower preva-
lence of anemia in our patients. 
Patients with ACS and anemia are commonly managed 
conservatively in routine clinical practice,[4,5,23–25] with a 
lower likelihood of receiving potent antithrombotic drugs 
and undergoing coronary angiography or other intensive 
therapies. Therefore, little information exists about patients 
with high-risk ACS and anemia admitted to critical care 
units. In our opinion this is a crucial issue, since these pa-
tients are usually fully candidates to intensive therapies. 
Despite the performance of coronary angiography was less 
common in patients with anemia from our series, this inva-
sive approach was selected in a high proportion of them 
(more than 90%). Interestingly, the performance of some 
ICCU procedures such as counterpulsation, non-invasive 
mechanical ventilation or renal replacement therapies were 
more common in this group, probably reflecting their higher 
profile of risk. In addition, a more conservative antithrom-
botic approach was used in patients with anemia, with a 
higher proportion of clopidogrel and lower of ticagrelor. 
Clopidogrel was the P2Y12 blocker more commonly used 
even in patients with normal haemoglobin values. This is 
also an interesting point, since recent data suggest that more 
antiplatelet drugs can be safely used in ACS patients with 
anemia with a careful assessment of ischemic and bleeding 
risk.[28] 
Anemia was associated with a higher prevalence of co-
morbidities and severity of coronary disease in our patients. 
However, no significant differences were observed regard-
ing the rate of revascularization according to anemia status. 
A potential reason for this might be the presence of more 
complex coronary lesions not suitable for revascularization 
in patients with anemia. The higher prevalence of comor-
bidities in patients with anemia might probably have con-
tributed to the worse outcomes observed in these patients. 
However, after adjusting for potential confounders, anemia 
was independently associated to a higher incidence of 
events at follow up, as observed by Uscinska, et al.[7] In our 
opinion, these data support the need for a careful manage-
ment and follow up in this group of complex ACS patients.  
This study has some limitations, such as the moderate 
sample size of subgroups and the moderate number of 
events. It was an observational study, so we cannot rule out 
the presence of selection bias or residual confounding. In 
addition, data regarding type of anemia or iron status was 
not available. Finally, a longer follow up might have con-
tributed to fully assess the association between anemia and 
outcomes. 
Despite these limitations, in our opinion this study re-
trieves interesting and novel data about the real prevalence 
of anemia and its impact on management and prognosis of 
high-risk ACS patients admitted to ICCU in routine clinical 
practice. Improving risk stratification and outcomes in this 
growing group of complex patients often excluded form 
clinical trials might lead to important clinical and social 
consequences. 
In conclusion, this study showed that almost one of each 
three patients with NSTEACS admitted to ICCU had ane-
mia at admission. Patients with anemia had a significantly 
higher prevalence of comorbidities and higher risk criteria at 
admission, although they underwent less often coronary 
angiography. Anemia was independently associated to poor-
er outcomes in this group of high risk ACS patients under-
going a contemporary management at ICCU. 
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